Prevalence of Essential Tremor in the Faroe Islands: A Population-Based Study

Eina H. Eliassen^a Monica Ferrer^b Shahin Gaini^{c–e} Elan D. Louis^{b, f, g}
Maria Skaalum Petersen^{a, c}

^aDepartment of Occupational Medicine and Public Health, The Faroese Hospital Systems, Tórshavn, Faeroe Islands; ^bDepartment of Neurology, Yale School of Medicine, Yale University, New Haven, CT, USA; ^cCentre for Health Science, Faculty of Health Sciences, University of the Faroe Islands, Tórshavn, Faeroe Islands; ^dInfectious Diseases Division, National Hospital Faroe Islands, Tórshavn, Faeroe Islands; ^eDepartment of Infectious Diseases, Odense University Hospital/University of Southern Denmark, Odense, Denmark; ^fDepartment of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, USA; ^gCenter for Neuroepidemiology and Clinical Neurological Research, Yale School of Medicine, Yale University, New Haven, CT, USA

Keywords

Essential tremor · Prevalence · Two-phase population-based design · Faroe Islands

Abstract

Background: No studies of the prevalence of one of the most common movement disorders, essential tremor (ET), have been undertaken in the Faroe Islands. Given the potential for founder effects in the Islands, and the highly genetic nature of ET, the Faroe Islands provide a particularly interesting setting in which to study the prevalence of ET. **Objective:** To estimate the prevalence of ET and study its characteristics. **Methods:** We used a 2-phase, population-based design, screening 1,328 randomly selected Faroese individuals aged ≥40 years. A subsample of 282 individuals who had returned the spirals and questionnaire was selected to participate in an in-person clinical evaluation. Tremor was systematically quantified by a senior movement disorder neurologist with

particular specialization in tremor using a reliable and valid clinical rating scale followed by the application of rigorous diagnostic criteria used by tremor investigators internationally. **Results:** The overall crude prevalence was 2.9%. The age-adjusted prevalence was 3.1%. There was an age-associated rise in prevalence; by age ≥70, prevalence reached 4.8%. Twenty six of 27 (96.2%) were previously undiagnosed. **Conclusions:** This is the first population-based study of the prevalence of ET in the Faroe Islands. The estimated prevalence was similar to studies using the same or comparable methodologies.

© 2019 S. Karger AG, Basel

Introduction

Essential tremor (ET) is among the most common neurological diseases and the most common tremor disorder. Estimates of the prevalence of ET have been

derived from diverse population settings in Africa, Europe, Asia, and the United States. In a meta-analysis, the prevalence was estimated to be 4.6% in the population age ≥ 65 years [1], and this increased with age, and especially with advanced age. Establishing a precise national prevalence estimate is important as knowledge about prevalence is of crucial importance to inform national policy development, planning and costs of health services. Additionally, subgroup differences in prevalence can offer initial clues about the existence of environmental or underlying biological factors that might be of etiologic or mechanistic importance. Finally, it is important for investigators to be able to confidently identify and count cases before they can study them further [1].

The hallmark feature of ET is kinetic tremor, which may be associated with varying degrees of functional disability [2–4]. The etiology of ET is complex; both genetic and environmental factors are likely contributors [5–9].

The Faroe Islands are located in the North Atlantic Ocean, between Norway and Iceland, and are inhabited by 49,121 individuals of whom 24,154 are of age 40 or older (January 1, 2016). Due to the isolated geographic location and homogenous population [10], the Faroe Islands have been the focus of epidemiological investigations of a number of neurological disorders. The prevalence of several movement disorders, such as Parkinson's disease (PD) [11, 12] and primary focal dystonia [13], is high, while multiple sclerosis [14, 15] and amyotrophic lateral sclerosis [16] are comparable to other European countries. Yet curiously, no studies of prevalence of one of the most common neurological disorders, ET, have been undertaken in the Faroe Islands. Given the potential for founder effects in the Islands and the highly genetic nature of ET [17], the Faroe Islands provide a particularly interesting setting for the study of the prevalence of ET. Thus, our aim was to estimate the prevalence of ET in a population-based sample in the Faroe Islands and to study the characteristics of ET in that population.

Methods

Study Population and Sampling Frame

We used a 2-phase, population-based study design. The study was undertaken between August 2016 and December 2017. From the 24,154 individuals aged ≥ 40 years living in the Faroe Islands, the names and addresses of 4,798 individuals aged ≥ 40 were obtained from the Faroese Population Registry. These individuals were selected based on 6 randomly selected birthdates (10th, 16th, 17th, 18th, 22th, and 30th). From this group, all 1,155 individuals aged ≥ 70 years were selected into the screening group, while the

remaining 1,845 were selected by random sampling using SPSS. Thus, the screening group comprised 3,000 Faroese individuals aged ≥ 40 years (Fig. 1).

First Phase Screening

In the first screening phase (September 2016 – December 2016), these 3,000 individuals received an invitation letter to participate in a study of lifestyle, diet, and neurological conditions. The invitation letter included a screening package that comprised questionnaires, a request for hand-drawn spirals, and a return stamped envelope. The questionnaires included 5 demographic questions, one question regarding smoking status, one question about years since most recent hospitalization, one question about handedness, and 7 screening questions for tremor (e.g., “do you often have shaking or tremor that you can't control,” “has a doctor diagnosed you as having familial tremor or benign ET,” “does your head often shake uncontrollably”).

The letter included instructions on how to draw 2 Archimedes spirals with each hand and 4 blank sheets of paper. As described in prior population-based settings [18–20], screenees were instructed to draw each spiral freely on a blank, standard 8.5 $\times$ 11-inch sheet of paper using a ballpoint pen, while seated at a table. They were instructed to center the paper at right angles horizontally directly in front of them and start at the center of the page, without lifting their pen. Prior to drawing the spirals, the participants were required to answer 5 questions about their use of caffeinated coffee, tea, and soda, cigarette smoking and the use of an asthma inhalator on that day, as each may produce or exacerbate tremor [20].

After one month, a reminder telephone call was made to individuals who had not returned their screening package. A total of 1,334 (44.5%) individuals returned the completed screening package. Of the remaining 1,666 individuals, 435 (26.1%) declined participation, 271 (16.3%) accepted participation but failed to return the screening packet, 11 (0.7%) returned the screening packet with no spiral drawings and/or no questionnaire, 30 (1.8%) died during the screening period, 12 (0.7%) letters were returned stating unknown address, and 907 (54.4%) were unreachable by telephone (e.g., not at home/no answer or telephone number was not available; Fig. 1).

Tremor on each spiral was rated by a senior movement disorders neurologist (E.D.L) who used an ordinal clinical rating scale (0–3.0), which included ratings of 0 (none), 0.5 (very mild), 1.0 (mild), 1.5 (mild-to-moderate), 2.0 (moderate), and 3.0 (severe), as used in prior epidemiological studies [21]. Based on data from the questionnaire and spiral scores, the participants were stratified into 4 groups: (1) those with a high likelihood of having ET (e.g., spiral ratings ≥ 1.5 on one or more dominant hand spirals or having been diagnosed previously with ET or having endorsed “head tremor” on the questionnaire), (2) those with an intermediate likelihood of having ET (e.g., both nondominant hand spiral ratings ≥ 1.5), (3) those with a low-intermediate likelihood of having ET (e.g., a single non-dominant arm spiral rating ≥ 1.5), and (4) those with a low likelihood of having ET (e.g., all spiral ratings ≤ 1). Hand dominance was a factor in this stratification scheme because in conditions such as enhanced physiological tremor, tremor occurs to a greater extent in the nondominant than dominant hand [22]. Hence, mild or mild-to-moderate nondominant hand tremor could be the result of enhanced physiological tremor than ET.

Fig. 1. Selection of screening population from 24,154 individuals, aged 40 and older. In total, 3,000 were selected for the final screening sample, of whom 1,334 participated.

Second Phase

In the second phase, a subsample of 282 individuals who had returned the spirals and questionnaire were invited to participate in an in-person clinical evaluation at the Department of Occupational Medicine and Public Health or in their own homes. All 85 individuals in group 1 were invited. Also, a randomly selected subsample of 197 individuals in group 2 ($n = 97$), group 3 ($n = 32$), or group 4 ($n = 68$) were also invited. A total of 227 (80.5%) individuals accepted and completed the in-person clinical evaluation, while 54 declined participation and one person had died. The participation rate was 78% (group 1), 85% (group 2), 84% (group 3), and 76% (group 4) (Fig. 2).

The in-person clinical evaluation was conducted by a trained nurse (E.H.E.) and included (1) anthropometric measures (body weight [kilograms] and height [cm]); (2) a questionnaire encompassing demographic data and data on medication usage, smoking habits, ethanol intake, tremor, and family history of tremor, and (3) a detailed videotaped tremor examination. The videotaped tremor examination included (1) an ET-specific metric comprised of one test for postural tremor and five for kinetic tremor (e.g., pouring, drinking) performed with each arm (12 tests total, with total tremor score = 0–36) [23], (2) the motor portion of the Unified PD Rating Scale [24] excluding an assessment of rigidity, and (3) an assessment of dystonia.

Diagnosis of ET and Other Neurological Conditions

ET diagnoses were assigned by E.D.L. by review of questionnaire data and the videotaped neurological examination and based on published diagnostic criteria (moderate or greater amplitude kinetic tremor during 3 or more activities or a head tremor in the absence of PD or another known cause [e.g., medication-induced tremor, tremor from hyperthyroidism]) [25]. These diagnostic criteria for ET were developed for a population-based genetic study and based on data from approximately 2,000 normal (nondiseased controls) [25], the criteria carefully specify the specific examination maneuvers during which tremor should be present and the severity of tremor that should be evident during these maneuvers to distinguish normal from ET. These criteria have been shown to be both reliable [26] and valid [27] and have been used by tremor investigators in the United States and internationally [28–39]. As in prior reports, borderline tremor was a diagnosis assigned to individuals who did not fully meet strict diagnostic criteria for ET (defined above) but were nonetheless considered by E.D.L. to have clinical features that aligned them more with ET than normal [23, 40]. The diagnosis of *dystonia* was confirmed using published diagnostic criteria [41], as was the diagnosis of PD [42].

Fig. 2. Selection of individuals for in-person clinical evaluation from 1,334 screenees, aged 40 and older, of whom 227 participated.

Statistical Analyses

Differences between the ET and non-ET group were tested with Student *t* test for continuous variables, and when evaluating categorical variables, chi square test or Fischer's exact test was used. Body mass index was calculated by dividing weight (kilograms) by squared height (meters).

Based on the number of ET cases diagnosed clinically, we standardized the proportions in each stratification group to the screening population using a direct standardization method and calculated the prevalence stratified by gender and age group: 40–49 years, 50–59 years, 60–69 years, and ≥70 years.

To estimate the overall prevalence in the Faroe Islands, the prevalence estimates from the screening group were adjusted by age and gender with regard to the Faroese population aged ≥40 years using a direct standardization method. Statistical analyses were performed using SPSS version 24.0.

Results

Characteristics of Study Population

A total of 1,334 individuals aged ≥40 years were screened for ET (Fig. 1). We excluded 6 individuals with

incomplete data. Hence, the current analysis focused on data from 1,328 participants (Table 1).

A total of 227 subjects participated in the in-person clinical evaluation. A diagnosis of ET was assigned to 27 of 227 individuals (11.9%): 15 out of 66 (22.7%) individuals in group 1, 11 of 82 (13.4%) individuals in group 2, 1 of 27 (3.7%) individuals in group 3, and 0 of 52 (0.0%) individuals in group 4. The ET and non-ET groups were comparable with respect to all variables except 4 variables from the screening and clinical exam questionnaires regarding tremor (Table 2). The ET group reported significantly more tremor than the control group. A total of 15 participants (55.6%) in the ET group responded positively to the question regarding presence of tremor, with a mean age of 47.4 years (median 58, range 12–75; *n* = 9) when the tremor first was noticed; 6 of 15 did not recalled the age. Eight of fifteen (53%) stated that the tremor was embarrassing, 6 (40%) answered “no,” and one (7%) did not know.

Clinical Characteristics of Persons with ET

Of the 27 participants with ET, head and/or jaw tremor was present in 12 individuals (44.4%) while none had voice tremor. The majority were right handed. Mean score for all 4 spirals for the ET group was 1.42 ± 0.27 (Table 3) and there was a significantly difference between right and left hand mean spiral score ($p < 0.01$). Of note, same significantly difference was observed in the screening group.

Prevalence

A total of 27 of 227 individuals were assessed to have ET – the crude overall prevalence = 2.93% (Table 4). The prevalence of ET increased with age ($p = 0.01$) and was more common in men than in women; however, the gender difference was not statistically significant ($p = 0.5$).

Discussion

Prior epidemiological work has established high prevalence of several movement disorders (i.e., PD [43] and primary focal dystonia [13]) in the Faroe Islands, providing an impetus to study the most common adult-onset movement disorder, ET. Also, given the potential for founder effects in the Islands, and the highly genetic nature of ET, the Faroe Islands provide a particularly interesting setting in which to study the prevalence of ET. Nonetheless, the prevalence of ET in this study was similar to that of other studies, as discussed below.

Table 1. Demographic characteristics of 1,328 study participants

Age in years, mean $\pm$ SD (median [range])	61.7 $\pm$ 13.0 (61.0 [40–98])
Gender, female, <i>n</i> (%)	703 (52.9)
Education, <i>n</i> (%)	
Less than high school graduate	389 (29.3)
High school graduate	87 (6.6)
Some college but not a college graduate	352 (26.5)
College graduate	380 (28.6)
Masters or doctorate degree	81 (6.1)
Missing data	39 (2.9)
Marital status, <i>n</i> (%)	
Married or remarried	937 (70.6)
Widowed	135 (10.2)
Never married	122 (9.2)
Divorced or separated	90 (6.8)
Other	43 (3.2)
Missing data	1 (0.1)
Place (i.e., Island) of residence, <i>n</i> (%)	
Suðurstreymoy	568 (42.8)
Eysturoy	304 (22.9)
Norðoyggjar	153 (11.5)
Suðuroy	128 (9.6)
Vágoy	78 (5.9)
Norðstreymoy	57 (4.3)
Sandoy	40 (3.0)
Current cigarette smoker, <i>n</i> (%)	265 (20.0)
Handedness, <i>n</i> (%)	
Right	944 (71.1)
Left	86 (6.5)
Ambidextrous, but mostly right	186 (14.0)
Ambidextrous, but mostly left	42 (3.2)
Totally ambidextrous	11 (0.8)
Reported “Do not know”	4 (0.3)
Missing	55 (4.1)
Cups of caffeinated coffee on the day of screening, mean $\pm$ SD (median [range])	1.9 $\pm$ 2.0 (1.0 [0–12])
Cups of caffeinated tea on the day of screening, mean $\pm$ SD (median [range])	1.5 $\pm$ 1.7 (1.0 [0–10])
Cups of caffeinated soda on the day of screening, mean $\pm$ SD (median [range])	0.1 $\pm$ 0.6 (0.0 [0–10])
Smoked cigarettes on the day of screening, <i>n</i> (%)	224 (16.9)
Number of cigarettes smoked on the day of screening, mean $\pm$ SD (median [range])	
All participants	1.2 $\pm$ 3.5 (0.0 [0–30])
224 participants who smoked on the day of screening	7.0 $\pm$ 5.6 (5.0 [1–30])
Used an asthma inhaler on the day of screening, <i>n</i> (%)	74 (5.6)
Hours since used asthma inhaler, mean $\pm$ SD (median [range])*	5.5 $\pm$ 3.8 (5.0 [0.5–16])
Spiral score, mean $\pm$ SD (median [range])	
Right hand spiral 1 score	0.61 $\pm$ 0.38 (0.5 [0.0–2.0])
Right hand spiral 2 score	0.59 $\pm$ 0.38 (0.5 [0.0–2.0])
Right hand mean spiral score	0.60 $\pm$ 0.36 (0.5 [0.0–2.0])
Left hand spiral 1 score	0.87 $\pm$ 0.41 (1.0 [0.0–2.0])
Left hand spiral 2 score	0.91 $\pm$ 0.40 (1.0 [0.0–2.0])
Left hand mean spiral score	0.89 $\pm$ 0.38 (1.0 [0.0–2.0])
Total (4 spirals) mean spiral score	0.74 $\pm$ 0.33 (0.75 [0.0–2.0])

* Sixty-nine participants.

Table 2. Comparison of 227 subjects with ET and without ET

	ET group	Non-ET group	<i>p</i> value
Number	27	200	
Age, years, mean $\pm$ SD	66.5 $\pm$ 11.7	62.2 $\pm$ 12.3	0.09
Gender, female, <i>n</i> (%)	10 (37.0)	93 (46.5)	0.35
Marital status, <i>n</i> (%)			
Married or remarried	13 (48.1)	138 (69.0)	0.14*
Widowed	6 (22.2)	22 (11.0)	
Never married	5 (18.5)	22 (11.0)	
Divorced or separate	2 (7.4)	14 (7.0)	
Other	1 (3.7)	4 (2.0)	
Education, <i>n</i> (%)			
Less than high school	8 (29.6)	54 (27.0)	0.34*
High school graduate	2 (7.4)	7 (3.5)	
Some college but not a college graduate	8 (29.6)	63 (31.5)	
College graduate	5 (18.5)	58 (29.0)	
Masters or doctorate degree	2 (7.4)	14 (7.0)	
Missing data	2 (7.4)	4 (2.0)	
Place (i.e., Island) of residence, <i>n</i> (%)			
Suðurstreymoy	10 (37.0)	106 (53.0)	0.35*
Eysturoy	4 (14.8)	28 (14.0)	
Norðoyggjar	5 (18.5)	27 (13.5)	
Suðuroy	5 (18.5)	15 (7.5)	
Vágoy	2 (7.4)	10 (5.0)	
Norðstreymoy	1 (3.7)	7 (3.5)	
Sandoy	0 (0.0)	7 (3.5)	
Current cigarette smoker, <i>n</i> (%)	9 (33.3)	40 (20.0)	0.11
BMI, kg/m ² , mean $\pm$ SD	28.0 $\pm$ 3.8	28.4 $\pm$ 4.6	0.66
Yes to question “do you drink alcohol,” <i>n</i> (%)	18 (66.7)	134 (67.0)	0.97
Yes to question “do you have a tremor,” <i>n</i> (%)	15 (55.6)	31 (15.5)	<0.0001
Yes to question “does anyone in your family have shaking/tremor,” <i>n</i> (%)	13 (48.1)	66 (33.0)	0.23*
Yes to question “do you often have shaking or tremor that you can’t control,” <i>n</i> (%)	8 (29.6)	25 (12.5)	0.08*
Yes to question “do other people often tell you that you have a tremor,” <i>n</i> (%)	9 (33.3)	8 (4.0)	<0.0001*
Yes to question “has a doctor diagnosed you as having familial tremor or benign essential tremor,” <i>n</i> (%)	1 (3.7)	4 (2.0)	0.19*
Yes to question “do you often have shaking or tremor in your hands or arms that you can’t control,” <i>n</i> (%)			0.013*
Yes, right arm	1 (3.7)	8 (4.0)	
Yes, left arm	0 (0.0)	2 (1.0)	
Yes, both arms	7 (25.9)	12 (6.0)	
Yes to question “does your head often shake uncontrollably,” <i>n</i> (%)	1 (3.7)	6 (3.0)	0.15*
Yes to question “does your voice almost always tremble when you talk,” <i>n</i> (%)	0 (0.0)	1 (0.5)	1.0*
Yes to question “does your hand usually tremble when you hold a pen or write your name,” <i>n</i> (%)	11 (40.7)	14 (7.0)	<0.0001*

* Fisher’s exact test.

p < 0.05; *t* test for continuous variables and chi-square or Fischer’s exact test for categorical variables. *p* values in bold indicate statistical significance. ET, essential tremor; BMI, body mass index.

The overall prevalence was 2.9%, whereas the age-adjusted prevalence was 3.1%. In our study, the study subjects were screened first and then examined based on a positive response to a screening questionnaire and spiral drawing. However, in our selection of individuals for clinical examinations, we did invite subjects from all 4 stratification groups, that is, also individuals not expected to have ET based on screening. This allowed us to calculate an estimated prevalence that approximated a situation in which all subjects had been examined. Com-

paring the Faroese prevalence with (1) population-based studies using either the same procedure (examination in a subset with extrapolation of findings up to the full sample) or a similar procedure (examining all) and (2) reporting the prevalence from age 40 and older, our prevalence estimate is higher than in a Italian study [44], which reported a crude prevalence of 0.8 but lower than a Turkish study [28] reporting a crude prevalence of 4% and a study from Finland [45] reporting a prevalence of 5.6%.

Table 3. Clinical characteristics of 27 participants with ET

Presence of head or jaw tremor, <i>n</i> (%) [*]	
Present in head	2 (7.4)
Present in jaw	7 (25.9)
Present in both	3 (11.1)
Presence of voice tremor, <i>n</i> (%) [*]	0 (0.0)
Handedness, <i>n</i> (%)	
Right	19 (70.4)
Ambidextrous, but mostly right	5 (18.5)
Missing data	3 (11.1)
Spiral score, mean $\pm$ SD (median [range])	
Right hand spiral 1 score	1.20 $\pm$ 0.42 (1.0 [0.5–2.0])
Right hand spiral 2 score	1.26 $\pm$ 0.40 (1.0 [0.5–2.0])
Right hand mean spiral score	1.23 $\pm$ 0.39 (1.25 [0.5–2.0])
Left hand spiral 1 score	1.60 $\pm$ 0.32 (1.5 [1.0–2.0])
Left hand spiral 2 score	1.65 $\pm$ 0.27 (1.5 [1.0–2.0])
Left hand mean spiral score	1.63 $\pm$ 0.26 (1.5 [1.0–2.0])
Total (4 spirals) mean spiral score	1.42 $\pm$ 0.27 (1.38 [0.88–2.0])
[*] On videotaped neurological examination. ET, essential tremor.	

Table 4. Prevalence estimates of ET stratified by age and gender

	Prevalence (%) 95% CI
Crude prevalence	2.93 (2.16–3.99)
Age group, years	
40–49	0.74 (0.18–2.32)
50–59	2.62 (1.30–4.98)
60–69	3.56 (1.93–6.78)
≥ 70	4.80 (3.19–7.15)
Age adjusted	3.11 (2.28–4.16)
Age standardized [*]	2.84 (2.64–3.06)
Gender	
Male	3.79 (2.59–5.65)
Female	2.10 (1.30–3.49)
Gender adjusted	2.90 (2.09–3.90)
Gender standardized [*]	2.96 (2.76–3.19)
[*] Standardized to Faroese population ≥ 40 years. ET, essential tremor.	

We observed the same age-associated rise in prevalence as other studies, which bolster the notion that age is a risk factor for ET. By age ≥ 70 , prevalence reached 4.80%. Further, our data indicate the slight male predominance, although the difference was not statistically significant. A meta-analysis of 28 population-based prevalence studies reported that while the majority of studies have not revealed a gender difference, a sizable minority (more than one-third) showed a statistically significant gender difference, with nearly all of those

showing a higher prevalence among men than women [1].

Of the 27 with ET, only one was previously diagnosed. Thus, our data indicate that Faroese do not seek medical attention for their tremor or the tremor may be mild enough so that their treating physicians do not make the diagnosis when they present for other complaints. These results are in line with other epidemiological studies showing that 80–100% of ET cases were previously undiagnosed [1].

The prevalence of PD in the Faroe Islands is high [43], as is the prevalence of certain forms of dystonia [13]. However, the current data indicate that the prevalence of ET, another involuntary movement, is comparable to that of other populations. This is of particular interest given the potential for founder effects in the Islands and the highly genetic nature of ET. It raises questions as to whether ET is less of a genetic disorder than often presumed and/or whether complex genetics play a larger role than traditionally thought. These issues have been discussed elsewhere [46–48].

This study has considerable strengths. First, the sample size in this population-based study is large, with data on 1,328 individuals, which corresponds to 5.5% of the entire Faroese population ≥ 40 years. More importantly, however, is that, tremor was (1) systematically quantified (2) by a senior movement disorder neurologist with particular specialization in tremor (3) using a reliable and valid clinical rating scale (4) followed by the application of rigorous diagnostic criteria used by tremor investigators in the United States and internationally [28–39].

There are also limitations. First, some of the screenees who were deemed to have a low-intermediate or low likelihood of ET and who were therefore not seen in person may have had ET. This is unlikely as our data showed that no individuals in group 4 (relatively normal spirals) had ET and virtually none in group 3 (mild tremor on spirals) had ET. Second, data on medication use were limited in the screening process, and therefore, we were not able to fully account for the effects of medication on the expression of hand tremor. This is not likely to have been important either; individuals with medication-induced tremors would have been carefully separated from ET during the videotaped examination. Third, the number of ET cases was limited; hence, some comparisons between the ET and non-ET group did not yield significant differences despite the expectation that they would (e.g., does anyone in your family have shaking or tremor? [Table 2]). Fourth, the study is undertaken within the context of a very homogeneous population. Thus, the results of this work may not generalize to largely mixed populations.

Participation bias could also be a potential problem. However, we carefully worded the screening letter and did not mention ET but rather described the study as one of lifestyle, diet, and neurological conditions. Thus, it is unlikely that people with ET were more likely to participate in the screening. A total of 1,334 (44.5%) individuals returned the completed screening package. Participants who returned the packages were on average 5 years younger and were 6% more likely to be female than nonparticipants. The prevalence of ET increased with age; hence, it is possible that we underestimated the overall prevalence by under ascertaining older individuals. This would not have affected our estimates of age-stratified prevalence, however. In the second phase with the clinical examinations, the highest number of decliners (22%) were in group 1, which were the individuals assessed to have high likelihood of having ET. Thus, a bias toward lower participation of those most likely to have ET may also have led to lower estimate.

In summary, in this large, population-based sample of 1,328 individuals, we estimate the age-adjusted prevalence to be 3.1%, which is similar to studies using the same or comparable methodologies.

Acknowledgments

The authors thank the participants of the study for their support.

References

- Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. *Mov Disord*. 2010 Apr;25(5):534–41.
- Louis ED, Barnes L, Albert SM, Cote L, Schneider FR, Pullman SL, et al. Correlates of functional disability in essential tremor. *Mov Disord*. 2001 Sep;16(5):914–20.
- Bain PG, Mally J, Gresty M, Findley LJ. Assessing the impact of essential tremor on upper limb function. *J Neurol*. 1993 Nov;241(1):54–61.
- Héroux ME, Parisi SL, Larocserie-Salgado J, Norman KE. Upper-extremity disability in essential tremor. *Arch Phys Med Rehabil*. 2006 May;87(5):661–70.
- Louis ED, Ford B, Frucht S, Barnes LF, X-Tang M, Ottman R. Risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study. *Ann Neurol*. 2001 Jun;49(6):761–9.
- Louis ED. Environmental epidemiology of essential tremor. *Neuroepidemiology*. 2008; 31(3):139–49.
- Clark LN, Louis ED. Essential tremor. *Handb Clin Neurol*. 2018;147:229–39.
- Jiménez-Jiménez FJ, de Toledo-Heras M, Alonso-Navarro H, Ayuso-Peralta L, Arévalo-Serrano J, Ballesteros-Barranco A, et al. Environmental risk factors for essential tremor. *Eur Neurol*. 2007;58(2):106–13.
- Tanner CM, Goldman SM, Lyons KE, Aston DA, Tetrad JW, Welsh MD, et al. Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology. *Neurology*. 2001 Oct;57(8):1389–91.
- Als TD, Jorgensen TH, Børglum AD, Petersen PA, Mors O, Wang AG. Highly discrepant proportions of female and male Scandinavian and British Isles ancestry within the isolated population of the Faroe Islands. *Eur J Hum Genet*. 2006 Apr;14(4):497–504.
- Petersen MS, Bech S, Nosova E, Aasly J, Farrer MJ. Familial aggregation of Parkinson's disease in the Faroe Islands. *Mov Disord*. 2015 Apr;30(4):538–44.
- Petersen MS, Guella I, Bech S, Gustavsson E, Farrer MJ. Parkinson's disease, genetic variability and the Faroe Islands. *Parkinsonism Relat Disord*. 2015 Jan;21(1):75–8.
- Joensen P. High prevalence of primary focal dystonia in the Faroe Islands. *Acta Neurol Scand*. 2016 Jan;133(1):55–60.
- Binzer S, Imrell K, Binzer M, Kyvik KO, Hilbert J, Stenager E. High inbreeding in the Faroe Islands does not appear to constitute a risk factor for multiple sclerosis. *Mult Scler*. 2015 Jul;21(8):996–1002.
- Joensen P. Multiple sclerosis: variation of incidence of onset over time in the Faroe Islands. *Mult Scler*. 2011 Feb;17(2):241–4.
- Joensen P. Incidence of amyotrophic lateral sclerosis in the Faroe Islands. *Acta Neurol Scand*. 2012 Jul;126(1):62–6.
- Louis ED, Ottman R. How familial is familial tremor? The genetic epidemiology of essential tremor. *Neurology*. 1996 May;46(5):1200–5.
- Louis ED, Hafeman D, Parvez F, Alcalay RN, Islam T, Siddique AB, et al. Prevalence of essential tremor in Araihaazur, Bangladesh: a population-based study. *Neuroepidemiology*. 2011;36(2):71–6.

Ethics Statements

All study procedures were approved by the local Ethical Review Committee of the Faroe Islands and by the Institutional Review Board at Yale University, with participation on a voluntary basis and signed informed consent obtained from each enrollee.

Disclosure Statement

There are no conflicts of interest or competing financial interest.

Funding Source

This work was supported by NIH grants R01 NS039422 and NS094607 (Dr. Louis).

Authors Contributions

E.D.L. and M.S.P. were responsible for the study concept and design. E.H.E. did the field work and performed the data analysis and manuscript preparation. E.D.L., M.S.P., and M.F. contributed to the data analysis. M.S.P., M.F., S.G., and E.L. contributed to conceptualization, manuscript editing, and review. The final copy has been read and approved by all contributing authors. All authors read and approved the final manuscript.

- 19 Louis ED, Hafeman D, Parvez F, Liu X, Alcalay RN, Islam T, et al. Tremor severity and age: a cross-sectional, population-based study of 2,524 young and midlife normal adults. *Mov Disord*. 2011 Jul;26(8):1515–20.
- 20 Hafeman D, Ahsan H, Islam T, Louis E. Betel quid: its tremor-producing effects in residents of Araihaazar, Bangladesh. *Mov Disord*. 2006 Apr;21(4):567–71.
- 21 Louis ED, Zhao Q, Meng H, Ding D. [Screening for action tremor in epidemiological field surveys: assessing the reliability of a semi-quantitative, visual, template-based scale for rating hand-drawn spirals](#). Volume 2. N Y: Tremor Other Hyperkinet Mov; 2012.
- 22 Louis ED, Ford B, Pullman S, Baron K. How normal is 'normal'? Mild tremor in a multi-ethnic cohort of normal subjects. *Arch Neurol*. 1998 Feb;55(2):222–7.
- 23 Louis ED, Ottman R, Clark LN. Clinical classification of borderline cases in the family study of essential tremor: an analysis of phenotypic features. *Tremor Other Hyperkinet Mov (N Y)*. 2014 Feb;4:220.
- 24 Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. *Mov Disord*. 2007 Jan; 22(1):41–7.
- 25 Louis ED, Ottman R, Ford B, Pullman S, Martinez M, Fahn S, et al. The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. *Neuroepidemiology*. 1997; 16(3):124–33.
- 26 Louis ED, Ford B, Bismuth B. Reliability between two observers using a protocol for diagnosing essential tremor. *Mov Disord*. 1998 Mar;13(2):287–93.
- 27 Louis ED, Pullman SL. Comparison of clinical vs. electrophysiological methods of diagnosing of essential tremor. *Mov Disord*. 2001 Jul; 16(4):668–73.
- 28 Dogu O, Sevim S, Camdeviren H, Sasmaz T, Bugdayci R, Aral M, et al. Prevalence of essential tremor: door-to-door neurologic exams in Mersin Province, Turkey. *Neurology*. 2003 Dec;61(12):1804–6.
- 29 Inzelberg R, Mazarib A, Masarwa M, Abuful A, Strugatsky R, Friedland RF. Essential tremor prevalence is low in Arabic villages in Israel: door-to-door neurological examinations. *J Neurol*. 2006 Dec;253(12):1557–60.
- 30 Gasparini M, Bonifati V, Fabrizio E, Fabbrini G, Brusa L, Lenzi GL, et al. Frontal lobe dysfunction in essential tremor: a preliminary study. *J Neurol*. 2001 May;248(5):399–402.
- 31 Farrer M, Gwinn-Hardy K, Muenter M, DeVrieze FW, Crook R, Perez-Tur J, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. *Hum Mol Genet*. 1999 Jan;8(1):81–5.
- 32 Dogu O, Sevim S, Louis ED, Kaleagasi H, Aral M. Reduced body mass index in patients with essential tremor: a population-based study in the province of Mersin, Turkey. *Arch Neurol*. 2004 Mar;61(3):386–9.
- 33 Gatto EM, Roca MC, Raina G, Micheli F. Low doses of topiramate are effective in essential tremor: a report of three cases. *Clin Neuropharmacol*. 2003 Nov-Dec;26(6):294–6.
- 34 Benito-León J, Alvarez-Linera J, Hernández-Tamames JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Louis ED. Brain structural changes in essential tremor: voxel-based morphometry at 3-Tesla. *J Neurol Sci*. 2009 Dec; 287(1-2):138–42.
- 35 Obwegeser AA, Uitti RJ, Turk MF, Strongosky AJ, Wharen RE. Thalamic stimulation for the treatment of midline tremors in essential tremor patients. *Neurology*. 2000 Jun; 54(12):2342–4.
- 36 Putzke JD, Uitti RJ, Obwegeser AA, Wszolek ZK, Wharen RE. Bilateral thalamic deep brain stimulation: midline tremor control. *J Neurol Neurosurg Psychiatry*. 2005 May;76(5):684–90.
- 37 Seijo-Martinez M, Del Rio MC, Alvarez JR, Prado RS, Salgado ET, Esquete JP, et al. [Prevalence of Essential Tremor on Arosa Island, Spain: a Community-based, Door-to-Door Survey](#). Volume 3. N Y: Tremor Other Hyperkinet Mov; 2013.
- 38 Sur H, İlhan S, Erdoğan H, Öztürk E, Taşdemir M, Börü UT. Prevalence of essential tremor: door-to-door survey in Sile, Istanbul, Turkey. *Parkinsonism Relat Disord*. 2009 Feb;15(2): 101–4.
- 39 Ozel L, Demir R, Ozdemir G, Ozyıldırım E, Aşar U, Ulvi H, et al. Investigation of the prevalence of essential tremor in individuals aged 18–60 in Erzurum. *Acta Neurol Belg*. 2013 Jun;113(2):127–31.
- 40 Louis ED, Hernandez N, Sebastian AA, Clark LN, Ottman R. Validity of probands' reports and self-reports of essential tremor: data from a large family study in North America. *J Neurol Sci*. 2018 Oct;393:45–50.
- 41 Fahn S. Concept and classification of dystonia. *Adv Neurol*. 1988;50:1–8.
- 42 Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. *Neurology*. 2001 Nov;57(10 Suppl 3):S34–8.
- 43 Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P. Prevalence and incidence of Parkinson's disease in The Faroe Islands. *Acta Neurol Scand*. 2008 Aug;118(2): 126–31.
- 44 Mancini ML, Stracci F, Tambasco N, Sarchielli P, Rossi A, Calabresi P. Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: results of a population-based study. *Mov Disord*. 2007 Mar;22(4): 540–5.
- 45 Rautakorpi I, Takala J, Marttila RJ, Sievers K, Rinne UK. Essential tremor in a Finnish population. *Acta Neurol Scand*. 1982 Jul;66(1): 58–67.
- 46 Clark LN, Louis ED. Challenges in essential tremor genetics. *Rev Neurol (Paris)*. 2015 Jun-Jul;171(6-7):466–74.
- 47 Testa CM. [Key issues in essential tremor genetics research: Where are we now and how can we move forward?](#) Volume 3. N Y: Tremor Other Hyperkinet Mov; 2013.
- 48 Ma S, Davis TL, Blair MA, Fang JY, Bradford Y, Haines JL, et al. Familial essential tremor with apparent autosomal dominant inheritance: should we also consider other inheritance modes? *Mov Disord*. 2006 Sep;21(9): 1368–74.